Literature DB >> 24717260

Toward understanding ubiquitin-modifying enzymes: from pharmacological targeting to proteomics.

Jennie R Lill1, Ingrid E Wertz2.   

Abstract

Ubiquitination is a highly conserved post-translational modification that regulates protein trafficking, function, and turnover. Ubiquitin ligases (E3s) conjugate ubiquitin polypeptides on substrates, whereas deubiquitnases (DUBs) reverse ubiquitination. Engineering of chemical antagonists and inhibitors of ubiquitin ligases and DUBs has considerably aided the study of enzymes that participate in ubiquitin modification of substrates. In addition, proteomic tools have been developed to characterize the enzymes, substrates, and modifications regulated by DUBs and E3s. Here we review inhibitors and antagonists that have been developed against DUBs and E3s, focusing on enzymes that participate in ubiquitin editing or in the reciprocal ubiquitin regulation of substrates. We outline the cellular biology that is regulated by these DUBs and E3s and highlight how the inhibitory compounds have improved our understanding of these pathways. Finally, we discuss the challenges and future directions for pharmacologically targeting ubiquitin-modifying enzymes, as well as the development of proteomic methods to evaluate ubiquitin modification of substrates.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2014        PMID: 24717260     DOI: 10.1016/j.tips.2014.01.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  15 in total

Review 1.  Ubiquitination in disease pathogenesis and treatment.

Authors:  Doris Popovic; Domagoj Vucic; Ivan Dikic
Journal:  Nat Med       Date:  2014-11-06       Impact factor: 53.440

2.  Assays for Posttranslational Modifications of Intermediate Filament Proteins.

Authors:  Natasha T Snider; M Bishr Omary
Journal:  Methods Enzymol       Date:  2015-11-06       Impact factor: 1.600

3.  Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma.

Authors:  Reinaldo Franqui-Machin; Mu Hao; Hua Bai; Zhimin Gu; Xin Zhan; Hasem Habelhah; Yogesh Jethava; Lugui Qiu; Ivana Frech; Guido Tricot; Fenghuang Zhan
Journal:  J Clin Invest       Date:  2018-06-04       Impact factor: 14.808

4.  Sculpting the proteome with small molecules.

Authors:  Randall W King; Daniel Finley
Journal:  Nat Chem Biol       Date:  2014-11       Impact factor: 15.040

Review 5.  Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson's Disease.

Authors:  Alice Nardin; Emilie Schrepfer; Elena Ziviani
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 6.  Deubiquitinating enzymes as oncotargets.

Authors:  Urszula L McClurg; Craig N Robson
Journal:  Oncotarget       Date:  2015

7.  Inhibition of ubiquitin-specific protease 2 causes accumulation of reactive oxygen species, mitochondria dysfunction, and intracellular ATP decrement in C2C12 myoblasts.

Authors:  Mayuko Hashimoto; Natsuko Saito; Haru Ohta; Kumiko Yamamoto; Asuka Tashiro; Kosuke Nakazawa; Osamu Inanami; Hiroshi Kitamura
Journal:  Physiol Rep       Date:  2019-07

Review 8.  Activity-based probes for the ubiquitin conjugation-deconjugation machinery: new chemistries, new tools, and new insights.

Authors:  David S Hewings; John A Flygare; Matthew Bogyo; Ingrid E Wertz
Journal:  FEBS J       Date:  2017-03-10       Impact factor: 5.542

Review 9.  Drugging the undruggables: exploring the ubiquitin system for drug development.

Authors:  Xiaodong Huang; Vishva M Dixit
Journal:  Cell Res       Date:  2016-03-22       Impact factor: 25.617

10.  E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia.

Authors:  Monica Benini; Silvia Fortuni; Ivano Condò; Giulia Alfedi; Florence Malisan; Nicola Toschi; Dario Serio; Damiano Sergio Massaro; Gaetano Arcuri; Roberto Testi; Alessandra Rufini
Journal:  Cell Rep       Date:  2017-02-21       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.